We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases.
GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies
With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.
GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies
With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $49M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Andera Par... | anderapart... |
| - | OrbiMed | orbimed.co... |
| - | Arix Biosc... | arixbiosci... |
| - | Horizon Te... | horizontec... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.06.2017 | Series B | $45M | Arix Biosc... |
| 21.01.2016 | - | $4M | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.11.2025 | Alentis Strengthens Management Team with Key Appointments | Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Coun... |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look like takeout targets — including one that could jump more than 1,000% | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past few years. AstraZeneca This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now Seve... |
| 05.05.2021 | LOGICBIO THERAPEUTICS, INC. LogicBio Therapeutics : Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | LEXINGTON, Mass. - LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, announced sever... |
| 27.04.2021 | ARIX BIOSCIENCE PLC LogicBio announces clinical and corporate updates | Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announce... |
| 30.06.2017 | Term Sheet — Friday, June 30 | ET CETERA New Money: Headspace, a Los Angeles-based maker of a meditation app, has raised $36.7 million in funding from Spectrum Equity. Headspace would not comment on its valuation but said it has increased from the reported $250 million v... |
| 29.06.2017 | LogicBio Therapeutics Raises $45M in Series B Funding | LogicBio Therapeutics Inc., a Cambridge, MA-based gene therapy company, raised $45m in Series B financing. The round was led by Arix Bioscience plc (LSE: ARIX) with participation from new investors OrbiMed, Edmond De Rothschild Investment P... |
| 29.06.2017 | Arix Bioscience Leads $45M Series B for LogicBio Therapeutics | Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed Series B financing round raising $45 million for LogicBio Therapeutics Inc., a ne... |
| 28.06.2017 | Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics | - |
| 28.06.2017 | Arix leads $45M series B for gene therapy biotech LogicBio | LogicBio Therapeutics has got off a $45 million series B funding round as it eyes the cash for disease-modifying gene therapies in rare childhood diseases. London-based investment firm Arix Bioscience led the oversubscribed round in the sem... |
| 21.01.2016 | OrbiMed-backed LogicBio raises $4M for hemophilia gene therapy | The company was founded in 2014 by Adi Barzel, a former Stanford University post-doc who completed his research in hemophilia. Its president and CEO is Leszek Lisowski, a former director of gene transfer at San Diego’s Salk Institute for Bi... |
Show more